# A Platform Trial Evaluating New Drugs or Combination in R/R Peripheral T-cell Lymphomas

> **NCT07018752** · PHASE1,PHASE2 · RECRUITING · sponsor: **The Lymphoma Academic Research Organisation** · enrollment: 49 (estimated)

## Conditions studied

- Peripheral T Cells Lymphoma (PTCL)

## Interventions

- **DRUG:** roginolisib
- **DRUG:** golcadomide
- **DRUG:** azacitidine

## Key facts

- **NCT ID:** NCT07018752
- **Lead sponsor:** The Lymphoma Academic Research Organisation
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-08-20
- **Primary completion:** 2028-04
- **Final completion:** 2030-01
- **Target enrollment:** 49 (ESTIMATED)
- **Last updated:** 2026-02-11

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07018752

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07018752, "A Platform Trial Evaluating New Drugs or Combination in R/R Peripheral T-cell Lymphomas". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT07018752. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*